cyrilzakka/clinical-trials huggingface dataset:
RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries

The objective of the study is To verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the use of 2.25mm diameter stents.

The objective of the study is to verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the use of 2.25mm diameter stents.

Eligibility Criteria:
Inclusion Criteria:

* Acceptable candidate for percutaneous coronary intervention (PCI),stenting, and emergency coronary artery bypass graft surgery
* Clinical evidence of ischemic heart disease, stable or unstable angina, silent ischemia and/or positive functional study
* Informed consent
* Patient agrees to comply with specified follow-up evaluations at same investigational site
* Single target lesion or two target lesions located in separate coronary arteries
* De novo lesion(s) in native coronary artery(ies)
* Target lesion(s) ≤ 27 mm in length
* Target vessel(s) have reference vessel diameter 2.25 mm to 3.5 mm

Exclusion Criteria:

* Within 7 days of implant platelet count \<100,000 cells/mm³ or \>700,000 cells/mm³; White Blood Cell (wbc) count \<3,000 cells/mm³; serum creatinine level \>2.5 mg/dl
* Acute myocardial infarction (MI) within 72 hrs of the index procedure (Q wave myocardial infarction(QWMI)/non Q wave myocardial infarction (NQMI) or any elevation of creatinine kinease myocardial-band isoenzyme(CK-MB) \> lab upper limit of normal)
* Previous PCI of target vessel(s) within 9 months prior to the procedure
* Planned PCI of any vessel within 30 days post-index procedure and/or planned PCI of target vessel(s) within 12 months post-index procedure
* History of stroke or transient ischemic attack(TIA) within prior 6 months
* Participating in investigational drug/device study that has not completed primary endpoint or interferes with study endpoints
* Inability to comply with required trial antiplatelet regimen
* Previous stent in target vessel unless it has been at least 9 months since stent placed and target lesion(s) is/are at least 15 mm from previous stent
* Target vessel(s) has/have other lesions w/ \> 40% diameter stenosis
* Unprotected left main coronary artery disease
Cognitive Behavioral Treatment of Pediatric Trichotillomania

This study will compare the effectiveness of cognitive-behavior therapy (CBT) to a minimal attention control (AC) condition for treatment of pediatric trichotillomania (TTM).

TTM is a persistent impulse control disorder in which the individual acts on urges to pull out his or her own hair. Onset typically occurs by adolescence, and TTM is often associated with significant functional impairment and distress. CBT is a type of psychotherapy designed to change problematic behaviors and thinking. It includes self-monitoring of hair-pulling urges and homework assignments to practice the use of cognitive and behavioral strategies.

Participants are assigned randomly to receive either CBT or AC for 8 weeks. Participants assigned to CBT receive weekly 1-hour sessions of CBT for 8 weeks; participants assigned to AC receive 6 telephone contacts and 2 in-person sessions for 8 weeks. After 8 weeks, CBT participants who respond to treatment enter Phase II, which lasts an additional 8 weeks and includes 4 in-person maintenance sessions. AC participants who are still symptomatic after 8 weeks are offered CBT.

Eligibility Criteria:
Inclusion Criteria:

* Primary diagnosis of Trichotillomania
* Minimum symptom duration of 6 months
* Presence of a stable parent or guardian

Exclusion Criteria:

* Other primary psychiatric diagnosis
* Bipolar illness, pervasive developmental disorder, thought disorder, current major depression, ADD/ADHD
* Concurrent psychotherapy
* Currently receiving psychotropic medications
Assessment of Right Ventricular Function by Cardiac MRI in Patients With Pulmonary Arterial Hypertension (IRMA)

Pulmonary hypertension (PH) is a pathophysiological condition defined by an increase in pulmonary arterial pressure above 20mmHg, which encompasses many very dissimilar conditions. Right ventricular function is the major determinant of survival in these patients. Currently, right ventricular function is estimated by trans-thoracic echocardiography via the measurement of standardised parameters. However, cardiac magnetic resonance imaging is now the reference technique for non-invasive quantification of volumes, mass, function of the right ventricle but can also be useful for the consideration of the pulmonary circulation. Thus, indices of function can be extracted and it plays an increasing role in the prognostic evaluation of the right heart function at diagnosis and at re-evaluation under treatment of pulmonary arterial hypertension. This work will initially focus on the assessment of right ventricular myocardial work by echocardiography and cardiac magnetic resonance imaging in comparison with invasive haemodynamic data.


Eligibility Criteria:
Inclusion Criteria:

* Patient with pulmonary arterial hypertension (group 1)
* Patient with cardiac MRI, echocardiography and right heart catheterisation within 1 month of each other

Exclusion Criteria:

* Patient with features of venous/capillary involvement
* Pulmonary arterial hypertension associated with with congenital heart disease
* Patient's decline to participate in the study
Improving Gait and Balance in Children With Hemiplegic Cerebral Palsy: Gait Myoelectric Stimulator Study

This research study will see if electrical stimulation increases heel strike (heel hits the floor first when walking), decreases limp, helps muscle contraction, and improves balance in children with a hemiplegic leg. An experimental electrical stimulation device called the Gait MyoElectric Stimulator (GMES) will be used to stimulate the shin and calf muscles.

Physical therapists focus on improving gait and balance in children with hemiplegic cerebral palsy (HCP). Functional electrical stimulation (FES) has the potential to improve strength and functional gait for children with HCP. The investigators hypothesize that a new FES system stimulating the dorsiflexor (DF) and plantarflexor (PF) muscles alternately at the correct time during gait, would lead to a significant improvement (p\<.05) in foot contact, gait symmetry and balance, compared to 12 weeks of a healthy lifestyle program called 5210.

Eligibility Criteria:
Inclusion Criteria:

* Children who are:

  1. Are age 5-18 years
  2. Have been walking independently (no walker or cane) for at least 18 months.
  3. Use co-contraction of DF and PF during walking based upon surface electromyography.
  4. Have a diagnosis of spastic hemiplegic CP, Gross Motor Function Classification System (GMFCS) Levels I-II

Exclusion Criteria:

* Children who:

  1. Have passive ankle range \<5 DF or \< 10 PF with hip and knee extended.
  2. Report uncontrolled seizures.
  3. Had orthopedic surgery (for example heel cord or hamstring lengthening)
  4. Have used tone reducing medications (Botox, Baclofen) in the last 6 months.
  5. Wear ankle foot orthoses that limit DF/PF motion.
  6. Have low motivation/tolerance for electrical stimulation.
  7. Have parents/caregivers who are not able or willing to assist with the protocol for 6 months.
  8. Have low tolerance to electrical stimulation in screening process.
Signature Personalised Patient Care System With the Vanguard Knee System Study

The purpose of this study is to determine whether the percentage cases which have ideal mechanical axial alignment using the Vanguard total Knee implant with the Signature cutting blocks is higher than those without the use of Signature when measured immediately post-operatively.

The purpose of this study is to determine whether the percentage cases which have ideal mechanical axial alignment using the Vanguard total Knee implant with the Signature cutting blocks is higher than those without the use of Signature when measured immediately post-operatively. Other outcomes will include knee assessments and patient questionnaires.

Eligibility Criteria:
Inclusion Criteria:

* painful and disabled knee joint resulting from osteoarthritis, rheumatoid arthritis, traumatic arthritis where one or more of the knee compartments are involved
* correction of varus, valgus or posttraumatic deformity
* correction or revision of unsuccessful osteotomy (wedge cut from bone to improve alignment), or arthrodesis (fusion)
* need to obtain pain relief and improve function
* ability and willingness to follow instructions, including control of weight and activity level.
* a good nutritional state
* must have reached full skeletal maturity
* able and willing to undergo an MRI scan

Exclusion Criteria:

* infection
* sepsis
* osteomyelitis
* failure of a previous joint replacement
BMAC Enhanced Coronary Artery Bypass Grafting (CABG)

Injection of concentrated bone marrow cells into the myocardium during CABG procedure.

Injection of autologous concentrated bone marrow cells into the myocardium during CABG procedure.

Eligibility Criteria:
Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be enrolled in the trial:

* Age 18 years and ability to understand the planned treatment.
* Patients with ischemic congestive heart failure requiring by pass surgery
* Congestive heart failure with ejection fraction 40%.
* Serum bilirubin, SGOT and SGPT 2.5 time the upper level of normal.
* Serum creatinine \< 3.0 or no dialysis.
* NYHA performance status \> 3.
* Negative pregnancy test (in women with childbearing potential).
* Subject has read and signed the IRB approved Informed Consent form
* Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000, Creatinine ≤ 3.0 mg / Dl, and/or no dialysis, INR ≤ 1.6 unless on Coumadin, or PTT \<1.5 x control (to avoid bleeding complications) Patients on Coumadin will be corrected prior to the procedure and must have an INR\<1.6 at the time of randomization/surgery

Exclusion Criteria:

Subjects will be excluded if they meet any of the exclusion criteria:

* Female who is pregnant or nursing, or of child bearing potential and is not using a reliable birth control method, or who intend to become pregnant during the tenure of this study.
* History of Prior Radiation Exposure for oncological treatment.
* History of Bone Marrow Disorder (especially NHL, MDS) that prohibit transplantation.
* History of abnormal Bleeding or Clotting.
* History of Liver Cirrhosis.
* Acute Myocardial Infarction \< 4 weeks from treatment date.
* Known active malignancy or results outside of normal limits from the following tests: PAP, Chest X-ray, PSA, Mammogram, Hemocult unless follow-up studies reveal patient to be cancer free.
* Active clinical infection being treated by antibiotics within one week of enrollment
* Terminal renal failure with existing dependence on dialysis
* Inability or unwillingness to comply with the treatment protocol, follow-up, research tests, or give consent.
* Unable to have 250cc bone marrow harvested.
* Medical risk that precludes anesthesia or ASA Class 5
* History of ventricular arrhythmia if AICD is not present.
* History of ventricular aneurysm.
* Concurrent surgery such as CABG with valve surgery.
* Minimally Invasive bypass surgery
* Life expectancy \<6 months due to concomitant illnesses
* Treatment with immunosuppressant drugs (including Prednisone \> 5 mg per day)
* Patients undergoing urgent by pass surgical procedure
* Patients with HGB A1C \> 8.5%
Cefiderocol in the Treatment of Multidrug-resistant Gram-negative Bacilli Infections, a Retrospective Study

Cefiderocol is a new antibiotic from the siderophore cephalosporin family for which there are few real-life data on its use in the treatment of infections with multidrug-resistant Gram-negative bacilli.

The circulation of bacterial strains multi-resistant to antibiotics is important at the Strasbourg University Hospital, so the investigators wish to report their local experience of the 1st uses of Cefiderocol in the treatment of infections with multi-resistant Gram-negative bacilli to antibiotics in order to better clarify the use of this antibiotic (therapeutic indication, method of administration)


Eligibility Criteria:
Inclusion criteria:

* Adult patient (≥18 years old)
* taken care of in the HUS and treated as part of routine care with Cefiderocol between 04/01/2020 and 08/31/2022.
* Subjects who have not expressed their opposition to the reuse of their data for scientific research purposes.

Exclusion criteria:

- Patient who has expressed his opposition to the retrospective reuse of his data for scientific research purposes.
Do Common Physical Tests Predict Injury or Performance

Field tests are convenient, simple tests that serve as estimates of components of athletic performance like power speed, and agility. It is thought clinically, that those who do best at these tests will perform the best in their sport and/or be the least likely to get injured. The converse is also thought to be true. The objective of this study is to administer field tests to athletes at the beginning of each season and then follow athletes over several years, tracking their injuries and their performance statistics. In this way, the investigators can determine if the clinical supposition is true and that the results of field tests are associated with injury or performance

11 physical performance tests were examined to determine their ability to predict injury

Eligibility Criteria:
Inclusion Criteria:

* age18-23
* member of the university's varsity teams

Exclusion Criteria:

* injured or recently injured prior to testing
* diagnosed current neurological issue
* recent (within 6 weeks) surgery where strenuous physical testing would be contraindicated
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1

The purpose of this study is to assess optimal dosage of buprenorphine on a thrice weekly schedule in a pilot clinical trial.


Eligibility Criteria:
Please contact site for information.
Does Implementing a Urinanylsis Protocol Based on Symptoms Decrease Length of Stay in the Emergency Department?

The implementation of nursing urinanlysis protocols based off of symptoms of urinary infections will significantly decrease the length of a patient's stay in the Emergency Department.


Eligibility Criteria:
Inclusion Criteria:

* patients between 16 and 65 years of age complaining of any of the following: dysuria, hematuria, urinary frequency, urinary urgency

Exclusion Criteria:

* any person less than 16 or greater than 65 years of age, history of kidney disease or transplant, foley catherization within the last 30 days, on immuno-suppresent and/or receiving chemotherapy
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung

Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma metastatic to the lung.


Eligibility Criteria:
Inclusion Criteria:

* Histologically proven, Progressive or recurrent high grade osteosarcoma metastatic to the lung
* Patients with histologically proven, fully malignant high-grade osteosarcoma of bone
* Measureable pulmonary metastases
* Less than grade 3 neuropathies, insignificant decreases in cardiac or auditory function
* ECOG performance status of 0, 1 or 2
* FEV1 of 50% or greater of predicted value
* FEV1/FVC ratio of 65% or greater
* Serum creatinine of ≤ 1.5 mg/dl
* Total bilirubin ≤ 1.5mg/dl and SGOT or SGPT \< 2.5 times upper normal limit
* ANC of ≥ 1,000/mm3 and platelet count of ≥ 100,000/mm3

Exclusion Criteria:

* Grade 3 or higher painful neuropathy persisting after a prior platinum containing regimen
* Patients who are pregnant or are of childbearing potential and not using methods to avoid pregnancy
* Concurrent systemic chemotherapy
* Greater than Grade 2 pulmonary toxicity
* Pulmonary atelectasis
* Reactive airway disease which has resulted in hospitalization within the last year or which requires daily treatment with bronchodilator therapy
* Concurrent serious infections
* Unstable or serious concurrent medical condition
* Recent major surgery or thoracic radiation therapy or chemotherapy
* Significant pulmonary fibrosis secondary to prior radiation
* Major ventilatory distribution abnormalities
* Osteosarcoma secondary to radiation or premalignant conditions
* History of prior malignancy
* Low grade osteosarcoma, parosteal or periosteal sarcoma
Internet Based Cognitive Behavior Therapy for Procrastination: A Randomized Controlled Trial

The aim of this study is to examine the effects of cognitive behavior therapy (CBT) for procrastination, and to investigate whether it can be delivered via the Internet. Two treatment groups will be used, one with therapist contact and one without, as well as a wait-list control group. It is assumed that the treatment group with therapist contact will be superior to the treatment group receiving no therapist contact since procrastination can be partially explained as a self-regulatory failure. Both treatment groups are presumed to be superior to the wait-list control.


Eligibility Criteria:
Inclusion Criteria:

* Primary difficulties are caused by chronic and severe procrastination
* Swedish residency
* Fluent in Swedish
* Computer with internet access

Exclusion Criteria:

* Ongoing psychotherapy
* Ongoing psychotropic medication (unless stabilized for three months)
* Severe depression (\> 30 points on MADRS-S)
* Suicidal ideation
* Misuse of drugs or alcohol
* Bipolar disorder
* Schizophrenia or psychosis
Efficacy of Cognitive Behavior Therapy in the Treatment of Chronic Pelvic Pain in Women

This will be the pilot study trial. The target population will be 30 individuals with Chronic Pelvic Pain (CCP). There will be 02 groups, Experimental Group and Control Group. The primary outcome measure will be Impact of Female Chronic Pelvic Pain Questionnaire (IF-CPPQ). The experimental group will receive CBT spread over 12 sessions.


Eligibility Criteria:
Inclusion Criteria:

1. Women of reproductive age.
2. Women with Chronic Pelvic Pain having no pathological or anatomical causes.
3. Women with Overactive Bladder Syndrome.
4. Women with Vulvodynia. -

Exclusion Criteria:

1. Women experiencing perimenopause or menopause.
2. Women with medical, or gynecological or hormonal abnormalities.
3. Women with mental disorders.
4. Women who use substances. -
Anodal Transcranial Direct Current Stimulation Over the Contralesional Hemisphere on Motor Recovery in Subacute Stroke Patients

Upper limb recovery is not predicted by the initial severity of paralysis and the parameters reflecting the integrity of the corticospinal tract (e.g. motor evoked potential, fractional anisotropy in diffusion tensor imaging). Although the inhibition of the contralesional hemisphere is known to be beneficial for the upper limb recovery after stroke in previous studies, this is not proven in the severely paralyzed upper limb. And the studies using the noninvasive stimulation in subacute stroke is lack. In addition, the role of contralesional (unaffected) hemisphere is known to be playing the important role in severe stroke.

In this randomized, double-blind, sham-controlled studies, the patients with subacute stroke (\<3 months after stroke onset), severe paralysis of the upper limb with poor prognosis (poor motor score and no response of motor evoked potential recorded in the extensor carpi radialis muscle) will be recruited. Interventional group will receive the 25 mins of anodal transcranial direct current stimulation (tDCS) over the contralesional premotor area plus 25 mins of robotic arm training per session for 10 sessions in 2 weeks. Control group will receive the same treatment except for sham tDCS instead of anodal tDCS over the contralesional premotor area. Functional outcome will be measured before and after the intervention (baseline, immediately after the intervention and 1 month after the intervention). Cortical activation pattern will be measured by the electroencephalography (EEG) at baseline and immediately after the intervention.


Eligibility Criteria:
Inclusion Criteria:

* Age: 18-85 years old
* Ischemic or Hemorrhagic stroke confirmed by the MRI or CT
* First-ever stroke
* \< 3 months after stroke
* Unilateral upper limb weakness due to the stroke and meets the following all conditions: (1)Shoulder Abduction Finger Extension (SAFE) score (range 0-10) revealing the motor paralysis is below 8 (lower score mean worse function)), (2)Fugl Meyer Assessment score in the affected upper extremity is 25 or under 25. (3)No response in the motor evoked potential recorded on the affected extensor carpi radialis muscle,

Exclusion Criteria:

* recurrent stroke
* history of the other brain injury (e.g. traumatic brain injury)
* poor cognitive function (score of korean version of mini-mental state exam is 15 or below 15).
* Poor cooperation due to delirium or problems in the consciousness
* Uncontrolled or unstable medical conditions.
* Pregnant
* Scalp problems which interfere with the tDCS application
* Robotic arm training can not be applied due to the unstable sitting posture or head control, or arm pain.
* Metals in the head (e.g. clip, coil)
* Cardiac pacemaker or cochlear implants
Effect of Oral Feeding on Patients With Chronic Obstructive Pulmonary Disease

This is a prospective, randomized controlled clinical trail that involved patients with Chronic Obstructive Pulmonary Disease.The goal of this clinical trial is to compare the clinical effect of Oral Tubes vs Nasogastric Tubes in patients with Chronic Obstructive Pulmonary Disease. The main questions it aims to answer are:

Compared to Nasogastric Tube Feeding, can the Oral esophageal Tube Feeding better improve the nutritional status and pulmonary infection

This is a prospective, randomized controlled clinical trail that involved patients with Chronic Obstructive Pulmonary Disease.The goal of this clinical trial is to compare the clinical effect of Oral Tubes vs Nasogastric Tubes in patients with Chronic Obstructive Pulmonary Disease. The main questions it aims to answer are:

Compared to Nasogastric Tube Feeding, can the Oral esophageal Tube Feeding better improve the nutritional status and pulmonary infection

Participants will be divided into two groups randomly, with different nutritional support respectively.

Eligibility Criteria:
Inclusion Criteria:

* A diagnosis of COPD confirmed by spirometry
* ≥18 years of age
* Sinus rhythm ≥50/min and \< 120/min at inclusion
* Written informed consent

Exclusion Criteria:

* Known hypersensitivity to metoprolol or related derivatives
* Sinus bradycardia (resting heart rate \< 50/min)
* Sick sinus syndrome unless treated with a pacemaker
* Atrial fibrillation/flutter
* Clinical signs or previous diagnosis of heart failure, angina pectoris, myocardial infarction, cerebrovascular disease, or critical peripheral ischemia